参芍软肝汤联合血脂康对非酒精性脂肪肝患者血脂、肝功能及炎性因子指标的影响

目的:探讨参芍软肝汤联合血脂康对非酒精性脂肪肝(NAFLD)患者血脂与肝功能及炎性因子指标的影响。方法:选取116例NAFLD患者为研究对象,根据入院时间随机将其分为对照组和试验组,各58例。其中对照组患者给予血脂康药物治疗,而试验组患者在此基础上加用参芍软肝汤治疗,均治疗2个月。比较治疗前后两组患者血脂、肝功能及炎性因子的变化情况。结果:治疗后试验组患者血脂水平和肝功能明显改善,与对照组患者比较差异有统计学意义(P<0.05);试验组患者总有效率明显高于对照组,差异有统计学意义(P<0.05);试验组患者血清脂联素(APN)明显升高,但高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平则明显下降,与对照组比较差异均有统计学意义(均P<0.05)。经Pearson法分析得知,APN与疗效呈明显正相关(r=0.682,P<0.05),而hs-CRP、TNF-α及IL-6则与疗效明显负相关(r=-0.624,-0.732和-0.773,P<0.05);Logistic回归分析显示,病程和治疗方法是影响NAFLD疗效的独立危险因素(P<0.05)。结论:参芍软肝汤与血脂康两者联合可明显改善NAFLD患者的血脂水平及肝功能,这可能与炎性因子APN、hs-CRP、TNF-α及IL-6释放相关。

Effects of Shenshao Ruangan Decoction combined with Xuezhikang on serum lipid,liver function and inflammatory factors in patients with nonalcoholic fatty liver disease

Objective:To investigate the effects of Shenshao Ruangan Decoction combined with Xuezhikang on blood lipid,liver function and inflammatory factors in patients with nonalcoholic fatty liver disease(NAFLD).Methods:116 cases of non-alcoholic fatty liver patients treated in our hospital from June 2017 to July 2018 were randomly divided into control group and experimental group,58 cases in each group according to the time of admission.The control group was treated with Xuezhikang,while the experimental group was treated with Shenshao Ruanggan Decoction on the basis of the control group,all patients were treated for 2 months.The changes of serum lipid{total cholesterol(TC),triglyceride(TG),low density lipoprotein(LDL)},liver function{alanine aminotransferase(ALT),glutamyl transaminase(AST)and glutamyl transpeptidase(GGT)}and inflammatory factors{adiponectin(APN),high sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-6}were observed and compared before and after treatment.Results:After treatment,compared with the control group,the blood lipid level and liver function of the experimental group were significantly improved,the difference was statistically significant(P<0.05).The total effective rate of the experimental group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).Compared with the control group,the serum APN of the experimental group was significantly increased,but the levels of hs-CRP,TNF-αand IL-6 were significantly decreased,and the differences were statistically significant(P<0.05).Pearson analysis showed that APN was positively correlated with efficacy(r=0.682,P<0.05),while hs-CRP,TNF-αand IL-6 were negatively correlated with efficacy(r=-0.624,-0.732 and-0.773,P<0.05).Multiple logistic regression analysis showed that duration and treatment were independent risk factors affecting the efficacy of NAFLD(P<0.05).Conclusion:The combination of Shenshao Ruangan Decoction and Xuezhikang can significantly improve the blood lipid level and liver function in patients with non-alcoholic fatty liver disease,which may be related to the release of inflammatory factors APN,hs-CRP,TNF-αand IL-6,and is worthy of clinical promotion.